Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Jin Xian Huang"'
Autor:
Ho Yin Chung, Jin Xian Huang, Kam Ho Lee, Helen Hoi Lun Tsang, Chak Sing Lau, Shirley Chiu Wai Chan
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 14 (2022)
Background: Magnetic resonance imaging (MRI) is important in the management of axial spondyloarthritis (SpA). However, many MRI lesions are not exclusive to axial SpA. Further characterization of these lesions may lead to better clinical decisions. O
Externí odkaz:
https://doaj.org/article/55affa55d26f4a379cb6249abc694862
Publikováno v:
Frontiers in Medicine, Vol 7 (2020)
Background: Anti-tumor necrosis factor biological agents had been proved to have a dramatic effect in ankylosing spondylitis (AS). We aimed to determine the efficacy and safety of crossover effects of adalimumab vs. etanercept in AS patients.Methods:
Externí odkaz:
https://doaj.org/article/6af5ecdcf66e4acfa6bb9891319b8042
Autor:
Jin-Xian Huang, Guo-Wen Zhang
Publikováno v:
Drugs. 83:461-463
Publikováno v:
International Journal of Rheumatic Diseases. 26:11-12
Autor:
Ho Yin Chung, Jin Xian Huang, Shirley Chiu Wai Chan, Kam Ho Lee, Helen Hoi Lun Tsang, Chak Sing Lau
Publikováno v:
Medicine. 101(29)
We aimed to investigate the clinical, diagnostic, and imaging features of patients with late onset axial spondyloarthritis (SpA) with initial symptom manifestation aged over 45 years. Participants with axial SpA were consecutively recruited. Clinical
Autor:
Jin-Xian Huang, Wei-Min Tian, Chen-Xi Lin, Yun-Gang Yang, Wei-Wei Chen, Yu Chen, Ya-Ping Song
Publikováno v:
Translational Pediatrics. 10:773-782
Background Bronchial asthma (referred to as asthma in the present study) is the most common chronic airway inflammatory disease in childhood. The present study aimed to investigate the effect of 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] on VDR expressi
Autor:
Jin-Xian Huang1, Li-Jun Zhang1 zhanglj6@hku-szh.org
Publikováno v:
Archives of Rheumatology. Sep2021, Vol. 36 Issue 3, p458-460. 3p.
Publikováno v:
International Immunopharmacology. 116:109804
Publikováno v:
Rheumatology and Immunology Research. 1:25-29
Tumor necrosis factor inhibitor (TNFi) has been applied in the treatment of ankylosing spondylitis (AS) for many years but still with an unmed need due to inefficacy or intolerance. Current treatment guideline recommended the use of IL-17 inhibitors
Publikováno v:
Expert Review of Clinical Immunology. 16:745-750
Ixekizumab (IXE) is a high affinity IgG4 approved for the treatment of ankylosing spondylitis (AS). Recently, two phase III randomized clinical trials (COAST-V, COAST-W) showed significant and sustained improvements in signs and symptoms of AS as eva